A prospective, randomised, multicenter trial for surgical treatment of central retinal vein occlusion: results of the Radial Optic Neurotomy for Central Vein Occlusion (ROVO) study group
| Autor: | Werner Brannath, S. Brunner, T. Aggermann, Susanne Binder, Ilse Krebs, Irene Womastek, Paulina Haas |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Male
medicine.medical_specialty medicine.medical_treatment Visual Acuity Vitrectomy Ophthalmologic Surgical Procedures Triamcinolone Acetonide law.invention Cellular and Molecular Neuroscience Randomized controlled trial Central retinal vein occlusion law Multicenter trial Retinal Vein Occlusion medicine Humans Prospective Studies Fluorescein Angiography Prospective cohort study Glucocorticoids medicine.diagnostic_test business.industry Optic Nerve medicine.disease Fluorescein angiography eye diseases Sensory Systems Vein occlusion Surgery Ophthalmology Treatment Outcome Intravitreal Injections Female business Tomography Optical Coherence Ophthalmologic Surgical Procedure |
| Zdroj: | Graefe's Archive for Clinical and Experimental Ophthalmology. 251:1065-1072 |
| ISSN: | 1435-702X 0721-832X |
| DOI: | 10.1007/s00417-012-2134-1 |
| Popis: | To compare the surgical outcomes and evaluate the effectiveness of two treatments for central retinal vein occlusion (CRVO), radial optic neurotomy (RON) and intravitreal triamcinolone (IVT), in comparison to natural history.A prospective, placebo-controlled, randomised and multi-center study. Patients with CRVO were treated in three groups - with either RON, a single intravitreal injection of 4 mg triamcinolone acetonide, or a placebo treatment. The main outcome measures were change of VA (visual acuity) and proportion of eyes with a significant improvement (defined as3 lines logMAR scale) of VA from baseline to month 12.Ninety patients were included. Due to insufficient data, seven were excluded. Forty-seven percent (n = 18) of patients treated with RON showed an increase in VA, in comparison to 10 % (n = 2) of placebo-treated patients, and 20 % (n = 5) of patients treated with IVT. Significantly more patients showed an improvement in VA following RON than in the placebo group (p = 0.009). Significantly more patients showed an improvement in VA following RON than in the IVT group (p = 0.034). No significant difference was found when directly comparing improvement in VA following IVT and placebo (p = 0.667) treatment.Significantly (p = 0.007) more patients in the placebo group (35 %, n = 7) showed a deterioration (defined as3 lines LogMAR scale) in VA than patients in the RON group (8 %, n = 3).Our study showed that following treatment with RON, patients with CRVO display a significantly better long-term VA than untreated patients and patients treated with a single dose of IVT. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink